MA49693A - Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue - Google Patents

Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue

Info

Publication number
MA49693A
MA49693A MA049693A MA49693A MA49693A MA 49693 A MA49693 A MA 49693A MA 049693 A MA049693 A MA 049693A MA 49693 A MA49693 A MA 49693A MA 49693 A MA49693 A MA 49693A
Authority
MA
Morocco
Prior art keywords
arnrep
heterological
compositions
ensure
methods
Prior art date
Application number
MA049693A
Other languages
English (en)
Inventor
Darrell J Irvine
Tasuku Kitada
Mariane Bandeira Melo
Ely Blanton Porter
Der Neut Kolfschoten Marijn Van
Ronald Vogels
Ron Weiss
Original Assignee
Janssen Vaccines & Prevention Bv
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv, Massachusetts Inst Technology filed Critical Janssen Vaccines & Prevention Bv
Publication of MA49693A publication Critical patent/MA49693A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049693A 2017-07-28 2018-07-27 Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue MA49693A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US201762546259P 2017-08-16 2017-08-16

Publications (1)

Publication Number Publication Date
MA49693A true MA49693A (fr) 2020-06-03

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049693A MA49693A (fr) 2017-07-28 2018-07-27 Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue

Country Status (12)

Country Link
US (2) US11235051B2 (fr)
EP (1) EP3658179B1 (fr)
JP (1) JP7311489B2 (fr)
KR (1) KR102806640B1 (fr)
CN (1) CN111163799A (fr)
AU (1) AU2018306614B2 (fr)
BR (1) BR112020001052A2 (fr)
CA (1) CA3071011A1 (fr)
IL (1) IL272281B2 (fr)
MA (1) MA49693A (fr)
SG (1) SG11202000019RA (fr)
WO (1) WO2019023566A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194988A (zh) * 2018-12-14 2021-07-30 葛兰素史密斯克莱生物公司 异源初次免疫加强疫苗组合物及方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020146700A1 (fr) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Nanoparticules lipidiques
AU2020385683A1 (en) 2019-11-18 2022-06-30 Janssen Biotech, Inc. Vaccines based on mutant CALR and JAK2 and their uses
JP2023517644A (ja) * 2020-03-09 2023-04-26 アークトゥラス・セラピューティクス・インコーポレイテッド コロナウイルスワクチン組成物及び方法
WO2022009052A2 (fr) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
CN116171150A (zh) 2020-08-14 2023-05-26 阿克丘勒斯治疗公司 冻干脂质纳米颗粒的方法
WO2022180007A1 (fr) 2021-02-23 2022-09-01 Janssen Vaccines & Prevention B.V. Mutation de protéine d'enveloppe du vih stabilisant un trimère
CA3173950A1 (fr) 2021-03-22 2022-09-22 Tyson D. BOWEN Enzymes de modification de l'adn, fragments actifs et variants connexes et methodes d'utilisation
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
EP4396359A4 (fr) * 2021-09-02 2025-09-17 Replicate Bioscience Inc Alphavirus modifiés à protéines non structurales hétérologues
WO2023156505A1 (fr) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimère stabilisant les mutations de protéines d'enveloppe du vih r304v, n302m et t320l
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4255397A (en) 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
DK1497440T3 (da) 2002-04-25 2008-12-01 Crucell Holland Bv Stabile adenovirale vektorer og fremgangsmåder til propagering deraf
PT1497438E (pt) 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
US20050208020A1 (en) 2003-11-12 2005-09-22 Doolan Denise L Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
DK1711518T3 (da) 2004-01-23 2010-04-06 Angeletti P Ist Richerche Bio Vaccinebærere for chimpanse-adenovirus
WO2007104792A2 (fr) 2006-03-16 2007-09-20 Crucell Holland B.V. Adénovirus recombinés basés sur les sérotypes 26 et 48 et utilisation de ceux-ci
DK2146760T3 (en) 2007-04-30 2019-01-28 Medtronic Minimed Inc FILLING OF RESERVOIR, BUBBLE MANAGEMENT AND DELIVERY SYSTEMS FOR INFUSION MEDIA AND PROCEDURES
WO2010085984A1 (fr) 2009-02-02 2010-08-05 Okairos Ag Séquences d'acide nucléique et d'acides aminés d'adénovirus simiens, vecteurs les contenant et leurs utilisations
AU2010209938A1 (en) 2009-02-02 2011-08-25 Glaxosmithkline Biologicals Sa Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2011005799A2 (fr) 2009-07-06 2011-01-13 Novartis Ag Molécules d'arn autorépliquantes et leurs utilisations
PL3178490T3 (pl) * 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
WO2012082918A1 (fr) 2010-12-14 2012-06-21 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccins contre filovirus d'adénovirus de sérotype 26 et sérotype 35
EP3632463A1 (fr) * 2011-04-08 2020-04-08 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
EP3508219A1 (fr) 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Vaccins arn autoréplicatives prime - protein boost
GB2513768B (en) * 2012-07-06 2015-04-15 Novartis Ag Complexes of cytomegalovirus proteins and nucleic acids encoding such proteins
US20140271714A1 (en) * 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach
KR20190062617A (ko) 2014-09-03 2019-06-05 버베리안 노딕 에이/에스 면역 반응을 증대시키기 위한 방법 및 조성물
BE1023877B1 (fr) * 2015-05-21 2017-09-01 Glaxosmithkline Biologicals Sa Procédés et compositions pour l’induction d’une immunité protectrice contre une maladie et/ou une infection à filovirus

Also Published As

Publication number Publication date
IL272281B (en) 2022-12-01
KR102806640B1 (ko) 2025-05-12
AU2018306614B2 (en) 2024-08-29
US11235051B2 (en) 2022-02-01
JP2020528911A (ja) 2020-10-01
US20220111033A1 (en) 2022-04-14
SG11202000019RA (en) 2020-02-27
US20200230225A1 (en) 2020-07-23
IL272281B2 (en) 2023-04-01
WO2019023566A1 (fr) 2019-01-31
BR112020001052A2 (pt) 2020-09-08
US11964007B2 (en) 2024-04-23
EP3658179A1 (fr) 2020-06-03
KR20200037818A (ko) 2020-04-09
EP3658179C0 (fr) 2025-09-17
EP3658179B1 (fr) 2025-09-17
CA3071011A1 (fr) 2019-01-31
IL272281A (en) 2020-03-31
JP7311489B2 (ja) 2023-07-19
CN111163799A (zh) 2020-05-15
AU2018306614A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA49693A (fr) Méthodes et compositions pour assurer l'immunisation contre l'arnrep hétérologue
IL289046A (en) Preparations and methods for inhibiting antigens of a certain lineage
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
EP3271482A4 (fr) Compositions et méthodes pour inhiber l'expression génique du facteur xii
IL266398A (en) Liver organoid preparations, methods for their production and their uses
EP3328363A4 (fr) Compositions et méthodes d'immunomodulation
EP3679141C0 (fr) Méthodes et compositions pour inhiber l'expression de la ldha
EP3445407A4 (fr) Compositions et méthodes d'immunothérapie cellulaire
EP3510152A4 (fr) Méthodes et compositions pour moduler l'expression génique
SG11201703803WA (en) Targeted xten conjugate compositions and methods of making same
EP3353309A4 (fr) Compositions et méthodes pour l'édition génomique
DK3157959T3 (da) Monoklonale antistoffer mod her2-epitop og fremgangsmåder til anvendelse deraf
EP3802553A4 (fr) Compositions contenant du silicium et procédés d'utilisation associés
SI3356408T1 (sl) Humanizirana protitelesa proti človeškemu CD19 in postopki uporabe
DK3119797T3 (da) Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
MA71468A (fr) Compositions et méthodes pour diminuer l'expression de tau
MA43378A (fr) Compositions et méthodes pour la reduction de la réponse immunitaire contre récepteurs d'antigène chimériques
EP3436031A4 (fr) Nouvelle construction d'arn et méthodes d'utilisation de cette dernière pour améliorer les effets thérapeutiques de cellules cytotoxiques et de cellules souches
IL271144A (en) Methods and compositions for reducing the immunogenicity of chimeric notch receptors
EP3258925A4 (fr) Méthodes et compositions pour réduire la vidange gastrique
EP3151830A4 (fr) Conjugués anticorps anti-her2-maytansine et méthodes d'utilisation de ceux-ci
EP3291794A4 (fr) Méthodes et compositions pour favoriser la pousse des cheveux
EP3302588A4 (fr) Compositions et méthodes pour l'adhérence à des surfaces
EP3352800A4 (fr) Méthodes et compositions pour réduire les métastases
EP3436467A4 (fr) Nouvelles compositions et méthodes thérapeutiques